Pfizer Trims Altana From Pipeline

On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. The roflumilast decision highlights Pfizer's changing requirements and circumstances, as well as originator Altana's dependence on the compound.

On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. Roflumilast was returned to co-development partner and originator Altana AG , and ex-Asian rights to capravirine reverted to Shionogi & Co. Ltd. [See Deal][See Deal]

Pfizer says the decisions are part of its regular and routine review of pipeline opportunities. But they come just three...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo